Abstract
Oral propranolol, first-line therapy for infantile haemangioma (IH) threatening functional impairment or cosmetic disfigurement, readily crosses the blood-brain barrier. Subsequently therefore, there are concerns about potential effects on infant development. Phillips et al. followed 200 children prescribed propranolol, observing sedative effects during treatment and reported gross motor abnormalities in 13 of 188 children, 7 of whom had delayed age (17-20 months) at first walking.
This article is protected by copyright. All rights reserved.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.